Nanozyme-Mediated PROTACs Delivery for Targeted Protein Degradation and Ferroptosis Sensitization in Prostate Cancer - PubMed
4 hours ago
- #PROTACs
- #prostate cancer
- #ferroptosis
- Nanoengineered PROTAC platform (ARV@MIL-HA-ss-HA) improves delivery and efficacy of ARV-771 in castration-resistant prostate cancer (CRPC).
- Uses MIL-101 nanoparticles as carriers and nanozymes, modified with HA-ss-HA hydrogel for CD44-mediated tumor targeting and GSH-triggered release.
- Induces ferroptosis by converting H2O2 to hydroxyl radicals and depleting GSH, while ARV-771 degrades BRD4 to sensitize tumor cells.
- Demonstrated efficient BRD4 degradation, enhanced ferroptotic cell death, and superior antitumor efficacy with minimal systemic toxicity in CRPC models.
- Proposes a dual-action synergistic mechanism combining targeted protein degradation and ferroptosis sensitization for overcoming therapy resistance in CRPC.